

Electronic Acknowledgement Receipt

EFS ID:	5976841
Application Number:	10078949
International Application Number:	
Confirmation Number:	8454
Title of Invention:	OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
First Named Inventor/Applicant Name:	Stanley T. Crooke
Customer Number:	32650
Filer:	Jane E. Inglese/Stephanie Yakubov
Filer Authorized By:	Jane E. Inglese
Attorney Docket Number:	ISIS-5027
Receipt Date:	28-AUG-2009
Filing Date:	20-FEB-2002
Time Stamp:	16:55:37
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	LeDoan_NuclAcidRes_1987_86 43-8659.PDF	981146 d52f73c5ca08d12eac28d58011a286505c b9665	no	17

Warnings:

Information:

2	NPL Documents	Lee_Cell_843-854.PDF	1091061 2b86c9b8d367023ca2b0d16b3b2ca8d6d61d9	no	12
Warnings:					
Information:					
3	NPL Documents	Lee_BioorgMedChemLett_2001_1333-1337.PDF	397196 ce46bcb3b3bda008400037795642bc0570b43d	no	5
Warnings:					
Information:					
4	NPL Documents	Lee_EmboJ_2002_4663-4670.PDF	1268470 fae531a7468b624c506786c7b4ed119127788c4	no	8
Warnings:					
Information:					
5	NPL Documents	Lee_Nature_415-419.PDF	573559 c1b49c28c3601711eaddf8c305d6d1831d523db	no	5
Warnings:					
Information:					
6	NPL Documents	Leeds_NucleosidesNucleotides_1689-1693.PDF	278831 382bc988be8c1900578e07bc41d52eeaf6c767c	no	5
Warnings:					
Information:					
7	NPL Documents	Letsinger_NuclAcidsRes_3487-3499.PDF	470228 abca11f78990df3ad8900f181c26c4c102c7ba0	no	7
Warnings:					
Information:					
8	NPL Documents	Letsinger_PNAS_6553-6556.PDF	420822 686d6149b73bd851bc2807d36998b1d49679236	no	4
Warnings:					
Information:					
9	NPL Documents	Lewis_NatureGenetics_107-108.PDF	165300 e07f06d172136c6ba9dc14e31afed782cfc0808	no	2
Warnings:					
Information:					
10	NPL Documents	Li_PharmRes_1540-1545.PDF	552881 188c5477b4ed488d41a3285a83c2bc85615da	no	6
Warnings:					
Information:					

11	NPL Documents	Liao_NuclAcidsRes_1371-1377.PDF	669916 5aabbe3754c41f529802e9f5f5e6b12ef3e15ea	no	7
Warnings:					
Information:					
12	NPL Documents	Lima_PNAS_10010-10015.PDF	538634 f42182011d7d7d4100014db0ca15c60337a06c732d	no	6
Warnings:					
Information:					
13	NPL Documents	Lima_BioChem_390-398.PDF	1187156 ab7805db3ebcf01a8304967c231389051212e031	no	10
Warnings:					
Information:					
14	NPL Documents	Limbach_NuclAcidsRes_1994_2183-2196.PDF	1030805 891a27d414378d31b1b7b2231567ee123c132	no	14
Warnings:					
Information:					
15	NPL Documents	Lin_JAmChemSoc_1998_8531-8532.PDF	225514 422ef1c913d359d45c4ae4831d2d2bb5d0f83f1	no	2
Warnings:					
Information:					
16	NPL Documents	Lin_JAmChemSoc_3873-3874.PDF	979674 e1ba0718159dce0bdf4d3249d599bdcfc04cd	no	2
Warnings:					
Information:					
17	NPL Documents	Lin_FasebJ_1371-1377.PDF	1239361 0a98ac71adb4f64c091b73362a5c3a26cf269	no	7
Warnings:					
Information:					
18	NPL Documents	Lipardi_Cell_297-307.PDF	984008 59bd97313235cd3a2c5f0ebba71d26219ecd8de	no	11
Warnings:					
Information:					
19	NPL Documents	Liu_Science_868-871.PDF	315337 5a9301324e90257f8f5ec9a725f8a628b65ee4	no	4
Warnings:					
Information:					

20	NPL Documents	Liu_JAmChemSoc_1102-1109.PDF	217650 3c26d2cc58f9116c4d886c7657dbee38d597e5a	no	8
Warnings:					
Information:					
21	NPL Documents	Liu_ArterioThrombVascBiol_2207-2213.PDF	337991 6a6dc9f6f7862255c3eac548f126915c91a1649	no	8
Warnings:					
Information:					
22	NPL Documents	Lixin_BioChemBiophysResCommun_185-193.PDF	1764956 0202f9280d234a1f4b4c0a820f55a017b13b6ac	no	9
Warnings:					
Information:					
23	NPL Documents	Loakes_NuclAcidsRes_2001_2437-2447.PDF	1020621 8c4f4600f5d824f923c2145f94ab16f612b13d70	no	11
Warnings:					
Information:					
24	NPL Documents	Lukhtanov_BioconjugateChem_564-567.PDF	528856 cb1d858fcbef90c161ababf85132bf55d32c430	no	4
Warnings:					
Information:					
25	NPL Documents	Madden_DrugDiscovToday_415-425.PDF	1476532 520ef4de999ab0eb2881347850e1cd41be9d191	no	11
Warnings:					
Information:					
26	NPL Documents	Mahato_ExpertOpiniononDrugDelivery_3-28.PDF	3364592 7dd8d19169c75cac53a79737e074abdc08c4ffc5	no	26
Warnings:					
Information:					
27	NPL Documents	Manche_MolCellBiol_5238-5248.PDF	1365510 91ab8d9f7db71c0a388d72db86738cd130eb03c	no	11
Warnings:					
Information:					
28	NPL Documents	Manoharan_CurrOpinChemBiol_2004_570-579.PDF	865749 21cd3027b08bb0eeac1a6bdc010776aef027bbaf7	no	10
Warnings:					
Information:					

29	NPL Documents	Manoharan_BioorgMedChemL etts_1053-1060.PDF	513536 b6fe774f8b673ab5d3cd56eb303a95d792a 439	no	8
Warnings:					
Information:					
30	NPL Documents	Manoharan_Nucleosides_969-9 73.PDF	247496 a977b23d801297fcb517b497a9c8b17b05 ee030	no	5
Warnings:					
Information:					
31	NPL Documents	Manoharan_AnnNYAcadSci_30 6-309.PDF	160418 f6b8b3dc34c4a7e4ef613a2cc87cc1376bfb 9705	no	5
Warnings:					
Information:					
32	NPL Documents	Manoharan_BioorgMedChemL etts_2765-2770.PDF	310438 85576c6143865c0567166631a238d1770e ee0b	no	6
Warnings:					
Information:					
33	NPL Documents	Manoharan_TetrahedLetts_717 1-7174.PDF	273001 cb409c2bdad1549f6d8017e7b6ca1451515 9605	no	4
Warnings:					
Information:					
34	NPL Documents	Manoharan_TetrahedLetts_365 1-3654.PDF	211370 536c6dbd76db0c3dbd5a89508e4535cec7 be4ab	no	4
Warnings:					
Information:					
35	NPL Documents	Manoharan_BiochimBiophysAc ta_117-130.PDF	1191162 b7b0eb2bf6d78053b297405d7b61697eb 96ac0ef	no	14
Warnings:					
Information:					
36	NPL Documents	Manoharan_DesignerAntisense Oligonucleotides_303-349.PDF	3478312 31a3d96ed6e26b07b5110ed7753126b980d c75ef	no	50
Warnings:					
Information:					
37	NPL Documents	Manoharan_AntisenseNucleicA cidDrugDevelopment_103-128 PDF	518590 62b4fd136df5a1779fbeddb8d8138107b2e 06d29b	no	26
Warnings:					
Information:					

38	NPL Documents	Manoharan_AntisenseDrugTechnologyPrinciplesStrategisandApplications_391-467.PDF	7203252 d7c5d8ec06d87399348d13481316a8f8dc3649	no	39
Warnings:					
Information:					
39	NPL Documents	Marcus-Sekura_NucAcidsRes_5749-5763.PDF	1059573 78c9c25abed81e3e6d872943e0e8e4b52471051	no	15
Warnings:					
Information:					
Total Files Size (in bytes):			39479504		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					